Accordingly, findings from a preclinical study published in Nature Communications showed that the addition of a PP2A inhibitor, LB-100, to PD-1 blockade demonstrated synergy and resulted in durable ...

today announced that the first patient has been dosed with BBO-11818 in the Phase 1 KONQUER-101 trial for advanced solid tumors. BBO-11818 is an orally bioavailable small molecule dual inhibitor ...

Roughly 20% of individuals treated with immune checkpoint inhibitors respond ... or metastatic cancers eligible for ICIs increased from 1.54% in 2011 to 57.15% in 2020, then declined slightly ...

“Checkpoint inhibitor resistance remains a significant ... “Historically, patients who progress on PD-(L)1 therapy are estimated to have a ≤5% likelihood of response to PD-(L)1 rechallenge ...

CAN-2409 plus prodrug has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who ...

Unlike current immunotherapies such as CAR-T cell therapy and PD-1 inhibitors, HSV-1 VG161 directly targets tumours using a modified virus. Speaking on the mechanism of this therapy, Dr. Suman Karanth ...

with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31% ...

Purpose: This study aims to investigate the efficacy and safety of PD-1/PD-L1 inhibitors in the first-line treatment of esophageal squamous cell carcinoma (ESCC) and identify factors influencing ...

Work at Satellos Bioscience Inc. has led to the identification of new AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of muscular dystrophy.